Kyverna Therapeutics, Inc. (KYTX) Balance Sheet

NASDAQ: KYTXAssets, liabilities, debt and equity over 5 years.

KYTX balance sheet, 2025

December 31, 2025 · U.S. dollars

$293.8M assets = $61.5M liabilities + $232.3M equity

What it owns$293.8MCash & ST investments: $279.3M (95.0%)Cash & ST investments$279.3M · 95%Other current: $3.7M (1.3%)PP&E: $5.4M (1.8%)Other non-current: $5.5M (1.9%)=How it is financed$293.8MCurrent liabilities: $36.5M (12.4%)Current liabilities$36.5M · 12%Long-term debt: $24.7M (8.4%)Long-term debt $24.7MOther LT liabilities: $320,000 (0.1%)Shareholders’ equity: $232.3M (79.1%)Shareholders’ equity$232.3M · 79%

Both columns are drawn to the same scale: what KYTX owns equals what it owes plus shareholders’ equity. Hover a block for its value.

KYTX financial health

Current ratio7.75
Comfortable · current assets cover current liabilities 7.75×
Debt / equity0.12
Low leverage · $0.12 of debt for each $1 of equity
Equity / assets79.1%
Equity-funded · of assets funded by shareholders
Cash / debt961.9%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles0.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

KYTX balance sheet trends, 2021–2025

Kyverna Therapeutics, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$85.5M2021$293.8M2025+36.2%/yr
Total liabilities$131.7M2021$61.5M2025−17.3%/yr
Shareholders’ equity−$46.3M2021$232.3M2025—
Cash & short-term investments$76.1M2021$279.3M2025+38.4%/yr
Total debt$5.6M2021$29.0M2025+51.2%/yr
Net cash (debt)$70.5M2021$250.2M2025+$179.7M
Working capital$61.2M2021$246.5M2025+$185.3M
Book value per share−$1.792021$5.252025—
Current ratio4.8420217.752025+2.92
Debt / equity0.1820230.122025−0.06
Shares outstanding25.8M202144.3M2025+14.4%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

KYTX assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

KYTX liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

KYTX debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

KYTX balance sheet

Kyverna Therapeutics, Inc. annual balance sheet
20252024202320222021
Assets
Cash & short-term investments$279.3M$286.0M$57.5M$51.3M$76.1M
Cash & equivalents$124.1M$96.6M$34.6M$37.7M$76.1M
Short-term investments$155.2M$189.4M$22.9M$13.6M$0
Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other current assets$3.7M$4.6M$3.1M$1.9M$1.0M
Total current assets$283.0M$290.6M$60.7M$53.3M$77.1M
Property, plant & equipment (net)$5.4M$10.7M$10.6M$12.4M$7.8M
Goodwill & intangible assets$0$0$0$0$0
Long-term investments$0$0$0$0$0
Other non-current assets$5.5M$3.4M$3.9M$1.2M$593,000
Total assets$293.8M$304.6M$75.2M$66.9M$85.5M
Liabilities
Accounts payable$5.3M$4.6M$4.4M$1.5M$773,000
Short-term debt$4.0M$3.9M$2.9M$2.3M$814,000
Deferred revenue——$9.1M$7.7M$6.0M
Total current liabilities$36.5M$33.8M$19.9M$12.0M$15.9M
Long-term debt$24.7M$0$0$0$0
Lease obligations$4.3M$8.2M$9.1M$10.6M$5.6M
Other long-term liabilities$320,000$4.3M$6.2M$129.0M$115.8M
Total liabilities$61.5M$38.1M$26.0M$140.9M$131.7M
Shareholders' equity
Common stock & paid-in capital$1,000————
Retained earnings (deficit)−$424.8M−$263.5M−$136.0M−$75.7M−$46.8M
Accumulated other comprehensive income$97,000$105,000$4,000−$26,000—
Total shareholders' equity$232.3M$266.6M$49.2M−$74.0M−$46.3M
Key figures
Total debt$29.0M$8.2M$9.1M$10.6M$5.6M
Net cash (debt)$250.2M$277.7M$48.5M$40.8M$70.5M
Working capital$246.5M$256.8M$40.8M$41.3M$61.2M
Tangible book value$232.3M$266.6M$49.2M−$74.0M−$46.3M
Book value per share$5.25$6.95—−$2.87−$1.79
Shares outstanding44.3M38.3M—25.8M25.8M
Current ratio7.758.613.054.454.84
Quick ratio7.658.472.904.294.78
Debt / equity0.120.030.18——
Equity / assets79.1%87.5%65.4%−110.6%−54.1%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 26, 2026); data from EODHD.

KYTX financial position

At the end of fiscal 2025 (December 31, 2025), Kyverna Therapeutics had total assets of $293.8 million (down 3.6% from a year earlier), total liabilities of $61.5 million and shareholders' equity of $232.3 million. It held $279.3 million in cash and short-term investments against $29.0 million of debt, a net cash position of $250.2 million. Its current ratio was 7.75. In the latest quarter (ended June 30, 2026) total assets were $219.8 million and equity $165.5 million.

Related: KYTX income statement, KYTX cash flow statement, KYTX key metrics. See the KYTX stock overview for the latest quote and news.

KYTX balance sheet FAQ

What are Kyverna Therapeutics's total assets?

Kyverna Therapeutics reported total assets of $293.8 million at the end of fiscal 2025 (December 31, 2025), compared with $304.6 million a year earlier.

How much debt does Kyverna Therapeutics have?

Kyverna Therapeutics had $29.0 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.12.

How much cash does Kyverna Therapeutics have?

Kyverna Therapeutics held $279.3 million in cash and short-term investments at the end of fiscal 2025; with $29.0 million of debt that is net cash of $250.2 million.

What is Kyverna Therapeutics's book value?

Kyverna Therapeutics's shareholders' equity (book value) was $232.3 million at the end of fiscal 2025, or $5.25 per share.

What is Kyverna Therapeutics's current ratio?

Kyverna Therapeutics had current assets of $283.0 million and current liabilities of $36.5 million, a current ratio of 7.75 (it can cover its short-term obligations).

Biotechnology: balance sheet